Theravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month High - Here's What Happened

Key Points

• Theravance Biopharma reached a new 52-week high of $14.55 during trading, closing at $14.43 with a trading volume of 317,873 shares.
• Analyst ratings for the stock show mixed reviews, with Zacks Research lowering it to a "hold" while B. Riley has a "buy" rating with a $28 target price; the average target price among analysts is $23.00.
• Insiders own 6.90% of the company's stock, with significant recent activity including an SVP selling 10,000 shares, and institutional investors controlling 99.10% of shares.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $14.55 and last traded at $14.43, with a volume of 317873 shares changing hands. The stock had previously closed at $14.07.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Zacks Research lowered Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 15th. B. Riley assumed coverage on Theravance Biopharma in a research report on Friday, September 12th. They issued a "buy" rating and a $28.00 target price on the stock. BTIG Research boosted their target price on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a research report on Tuesday, June 17th. Finally, Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $23.00.

Theravance Biopharma Price Performance

The business's 50 day moving average is $12.98 and its 200 day moving average is $10.98. The stock has a market cap of $726.69 million, a price-to-earnings ratio of 60.13 and a beta of 0.04.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the transaction, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of TBPH. Vanguard Group Inc. grew its holdings in shares of Theravance Biopharma by 3.5% during the first quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company's stock worth $18,579,000 after purchasing an additional 69,919 shares during the last quarter. Park West Asset Management LLC grew its holdings in shares of Theravance Biopharma by 0.6% during the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock worth $16,112,000 after purchasing an additional 11,256 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Theravance Biopharma by 0.4% during the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company's stock worth $9,863,000 after purchasing an additional 3,416 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Theravance Biopharma by 16.5% during the second quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company's stock worth $5,952,000 after purchasing an additional 76,417 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of Theravance Biopharma by 10.9% during the fourth quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company's stock worth $4,665,000 after purchasing an additional 48,635 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.